Can-Fite BioPharma (NYSE:CANF) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note released on Sunday. The firm issued a sell rating on the stock.

Separately, D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, March 18th.

Can-Fite BioPharma Trading Down 3.1 %

CANF stock opened at $1.57 on Friday. The company has a market capitalization of $5.56 million, a P/E ratio of -0.88 and a beta of 1.12. The business has a 50 day simple moving average of $1.59 and a 200-day simple moving average of $1.86. Can-Fite BioPharma has a twelve month low of $1.29 and a twelve month high of $4.69.

Institutional Investors Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Rhumbline Advisers grew its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 26,880 shares of the company’s stock after buying an additional 9,935 shares during the quarter. Rhumbline Advisers owned 0.76% of Can-Fite BioPharma worth $44,000 as of its most recent filing with the SEC. Institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.